MannKind Corporation Stock News

MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, wit...

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn.

India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd.

MannKind Corporation (NASDAQ:MNKD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Andreas Argyrides - Oppenheimer Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Brandon Folkes - Rodman & Renshaw Operator Good afternoon, and welcom...

Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

Met primary objective demonstrating nintedanib DPI was safe and well tolerated Participants did not experience adverse events typically reported with oral nintedanib Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.